Gastrointestinal Endoscopy Market

Market Overview

The global Gastrointestinal Endoscopy Market was valued at approximately USD 7.4 billion in 2024 and is projected to reach USD 12.2 billion by 2033, growing at a CAGR of 5.8% during the forecast period (2025–2033).

Gastrointestinal endoscopy is a minimally invasive and therapeutic diagnostic procedure utilized to visualize the internal lining of the gastrointestinal (GI) tract using an endoscope. It plays an important role in the early diagnosis, detection, and management of a variety of GI diseases, such as colorectal cancer, gastroesophageal reflux disease (GERD), ulcers, inflammatory bowel disease (IBD), and polyps. Colonoscopy, gastroscopy, and capsule endoscopy are some examples of endoscopy to visualize and treat abnormalities of the digestive system. The increasing global burden of GI diseases, a growing focus on the importance of preventive healthcare screenings, and advances in modern endoscopic imaging capabilities (such as high-definition imaging and AI-assisted diagnostics) are some of the main drivers of market growth. A growing shift towards outpatient endoscopy services and the usage of robotic-assisted and disposable endoscopic systems further addresses procedural safety and efficiency, which will continue to inform user uptake and adoption in developed and emerging healthcare markets.

Market Dynamics

Market Drivers

Increasing Prevalence of Gastrointestinal Disorders and Cancers

The increase in the global prevalence of gastrointestinal (GI) disorders and cancers is one of the major factors for the expansion of the gastrointestinal endoscopy market. GI disorders, including colorectal cancer, gastroesophageal reflux disease (GERD), Crohn’s disease, and ulcerative colitis, are on the rise and the demand for GI diseases is expected to increase since early diagnosis of these disorders can help initiate endoscopy procedures.

According to the World Health Organization (WHO), colorectal cancer is the third most common cancer in the world with over 1.9 million new cases and 935,000 deaths in 2020. In the US, the American Cancer Society estimates that in 2024 there will be over 106,000 new cases of colon cancer and over 46,000 new cases of rectal cancer, emphasizing the importance of routine screening. Colonoscopy and upper GI endoscopy are still the gold standard for detection and prevention of diseases in the early stages.

Countries like the United States, Germany, Japan and South Korea implement national screening programs which adds to procedural volumes. There has also been a marked increase in GI disorders thought to be related to lifestyle factors, including poor diet, alcohol use and stress. The rising incidence of disorders such as GERD and peptic ulcers drives an increased demand for endoscopic diagnosis and treatment.

Technological Advancements and the Rise of AI-Assisted Endoscopy

Emerging and rapidly developing endoscopic devices are exponentially increasing the precision, safety, and efficiency of GI procedures, thus driving accelerated growth in the market. High-definition (HD) endoscopes; narrow-band imaging (NBI); confocal laser endomicroscopy; and capsule endoscopy have changed gastroenterology by allowing visualization of mucosal structures and early detection of pathology.

Notable developments are the use of artificial intelligence (AI) in endoscopic imaging. In 2022, Olympus Corporation released its EVIS X1 endoscopy system, with AI-based detection to support clinicians with the real-time identification of polyps and lesions. Recently, companies, such as Fujifilm and Pentax Medical have invested significant resources into artificial intelligence platforms that reduced the variability of the operator and improve the diagnostic yield.

A 2023 study published in The Lancet Digital Health showed that AI-augmented colonoscopy can significantly increase adenoma detection rates of up to 14%, potentially decreasing colorectal cancer mortality. In addition, capsule endoscopy (a pill-sized endoscopic device swallowed by the patient to collect imaging) is increasingly utilized to visualize the small bowel, particularly in a rural and outpatient setting, where traditional procedures are not possible. These innovations are attracting investments, promoting streamlined workflows, and enhancing patient comfort to broaden the use and acceptance of gastrointestinal endoscopy.

Market Restraints

High Cost of Endoscopic Equipment and Procedures

High costs for endoscopy equipment, procedures, and maintenance remain a major limitation to growth in the gastrointestinal endoscopy market. Investigative and advanced endoscopic systems like HD scopes, narrow-band imaging platforms, and other AI-assisted diagnostic tools involve high capital costs – a barrier for many of the small- and medium-sized facilities; especially in low- and middle-income countries (LMICs).

The cost of a full-featured video endoscope system is between USD 50,000 and over USD150,000, not including recurring costs such as disposable accessories for endoscopic procedures, cleaning and reprocessing equipment and maintenance contracts. To elaborate… endoscopic procedures, such as colonoscopy or ERCP, not only involve equipment costs but will also involve sedation fees, specialist fees, biopsy sampling tools, and a post-procedure anaesthetist’s monitoring fees.

In high-cost resource regions, endoscopic procedures can raise a patients overall treatment costs through complex and indirect costs. Many parts of the world, particularly in Asia, Africa and Latin America, do not have some form of universal healthcare and have limited reimbursement systems, which adds another layer of variability close to what a patient will be an ‘out of pocket’ expense. Furthermore, in rural and underserved areas, the cost of procedures fall directly on the patients themselves, further disincentivizing timely screening or follow-up visits.

Segmental Analysis

The Gastrointestinal Endoscopy Market is segmented by product, by application and end-user. Each segment plays a pivotal role in advancing the diagnosis and treatment of gastrointestinal (GI) disorders, with technological innovation and growing disease prevalence driving demand.

By Product

In 2024, endoscopes continue to dominate the market, contributing approximately 42.1% of the total share. This dominance is recognized due to the importance of shedding light on a diverse number of GI procedures from gastroscopy to colonoscopy and sigmoidoscopy. With rising incidences of cancers of the stomach or GI tract and disorders such as GERD and Crohn’s disease, there is a significant increase in the number of procedures being conducted.

The colonoscope and gastroscope types will remain the most commonly used due to their use in screening and diagnostics. The visualization systems segment is expected to expand at a robust rate due to improvements in HD imaging, narrow-band imaging (NBI) imaging and AI-assisted detection, which improve diagnostic accuracy and workflow.

The other instruments including biopsy forceps and snares are experiencing steady volume demand due to the necessity in therapeutic endoscopy and polypectomy procedures. The accessories segment is being influenced by a continued increase in procedural volume and the need for disposable items to maintain infection control standards.

By End-User

In 2024, hospitals had the largest share, accounting for 58.7% of total revenue. One of the reasons for this is they have high-volume patient care, skill gastroenterologists, and infrastructure to partner with specialty. Hospitals are the principal site of both diagnostic and interventional endoscopy, which includes advanced procedures like ERCP and EUS. Ambulatory Surgical Centers (ASCs) are growing in revenue with outpatient procedures being on the rise, pricing advantages, and less wait time for patients.

They are particularly important for routine colonoscopy and sigmoidoscopy. Favorable reimbursement and public acceptance of same-day diagnostic confirms they will continue to capture market share. Specialty clinics and diagnostic centers are also gaining traction, especially in urban and semi-urban areas due to the increasing emphasis on both early diagnosis and preventive care. These centers provide potentiality for basic endoscopic screening and support decentralizing GI diagnostics.

By Application

In 2024, colonoscopy had the largest share of the market, accounting for roughly 34.5% of the entire gastrointestinal endoscopy market. This is due to the global burden of colorectal cancer and increasing awareness of the importance of routine colon cancer screening. Increasing engagement in national screening programs like the U.S., Germany, and Japan is stimulating demand.

Colonoscopy is used widely and can detect and treat many conditions, especially polypectomy, and it also has the advantage of being a minimally invasive procedure. Upper GI endoscopy (esophagogastroduodenoscopy) is the next most significant area, mostly due to the increasing incidence of upper gastrointestinal conditions such as GERD, Barrett’s esophagus, and peptic ulcers. There is increasing use of upper GI endoscopy procedures for both diagnostic and surveillance reasons, particularly among the elderly contour.

Capsule endoscopy is also the fastest growing application currently due to both its non-invasive application and patient-friendly design, and it has been most helpful in detecting obscure gastrointestinal bleeding and small bowel abnormalities. ERCP (Endoscopic Retrograde Cholangiopancreatography) and enteroscopy are also on the rise due to their interventional nature when treating bile duct stones and obscure GI bleeding.

Although these advanced procedures are still limited in scope, they are expected to grow as the number of specialists performing these procedures rises and innovations in equipment become more expanded.

Regional Analysis

North America

In 2024, North America held the biggest share of the gastrointestinal endoscopy market at about 38.2% of global revenue. The United States is the leading contributor to this market based on the prevalence of diseases, advanced healthcare system, and increased screening for colorectal cancer. The Centers for Disease Control and Prevention (CDC) estimates that around 15 million endoscopic procedures are performed every year in the United States with colonoscopies being the majority.

Because of the leading companies in the industry: Boston Scientific, Medtronic, and Olympus Corporation they along with additional reimbursement opportunities; will have faster uptake of next generation endoscopy products and services. The incorporation of artificial intelligence (AI) and robotic-assisted systems to GI diagnostics further enhances market growth in this region.

Europe

Europe, the second largest regional market and boosting public health initiatives, an aging population, and increased awareness of early disease detection. Examples of established national colorectal cancer screening programs are Germany, United Kingdom, France, and Italy, which produce higher volumes of procedures. For example, the healthcare system in Germany provides biannual fecal occult blood testing and an every-ten-year colonoscopy for patients over 50 years of age, that allows early detection of GI issues, and establishes endoscopy as routine use in GI applications.

In addition, governments are injecting strong funding into healthcare innovation, along with public private partnerships, which are both encouraging high-definition imaging systems and minimally invasive procedures. Moreover, due to the geriatric population growth, and increased cases of inflammatory bowel disease (IBD), Europe will be an emerging and lucrative market for diagnostic and therapeutic endoscopy.

Asia Pacific

The Asia Pacific region is the fastest-growing geographic market and is projected to have a CAGR greater than 7% during the forecast period. Countries such as China, India, Japan, and South Korea are seeing a steady increase in gastrointestinal diseases due to urbanization, change in diet, and increased life expectancy.

Japan has one of the best healthcare systems in the world and has the highest penetration of endoscopy globally. China and India have also made large capital investments in healthcare infrastructure and are increasing access to diagnostic services in urban and semi-urban markets.

Furthermore, the increasing presence of local and international manufacturers and growing government support for cancer screening programs are speeding the rate of technology adoption. The region presents considerable growth opportunities for manufacturers of endoscopy systems due to the large number of patients and increasing demand for affordable diagnostics.

Latin America and Middle East & Africa

Latin America is growing moderately, driven by an increasing awareness of gastrointestinal diseases and an expanding landscape of diagnostic technologies. Countries such as Brazil, Mexico, and Argentina, are seeing more public health investment into increasingly modern hospitals. However, inconsistent reimbursement structures, and a lack of access to trained specialists in rural areas, continues to make full scale adoption difficult.

Nevertheless, public-private partnerships and the establishment of private diagnostic centers have been increasing access to GI endoscopy services, particularly for colorectal cancer screening. The Middle East & Africa is a developing market with substantial unrecognized opportunity. Growth in this part of the world is supported by increasing healthcare investment in countries like Saudi Arabia, UAE, and South Africa. Wherever subsidies are offered, governments are working to modernize facilities and expand specialized care.

Nevertheless, access remains variable from country to country, especially in lower-income countries where GI disorders go widely underdiagnosed because of awareness and access to healthcare. International aid programs and mobile diagnostic units are improving access gradually, and the introduction of inexpensive capsule endoscopy and disposable scopes are helping to address access taking into consideration a poor infrastructure.

Recent Development

1. July 2025: Olympus launched the EU‑ME3 Ultrasound Processor in the U.S. for advanced GI and pulmonary imaging.
2. April 2025: Fujifilm introduced the ELUXEO® 8000 system in Europe, featuring enhanced imaging and 4K resolution.
3. March 2025: Fujifilm commercialized the EN‑840T Double Balloon Enteroscope, winning the 2025 MedTech Breakthrough Award.